Stoke Therapeutics chair sells 4,355 shares after option exercise

Stoke Therapeutics Interim Executive Chair Arthur Tzianabos reported an option exercise and share sale involving the company’s common stock.

Rhea-AI Filing Summary

Stoke Therapeutics Interim Executive Chair Arthur Tzianabos reported an option exercise and share sale involving the company’s common stock. On March 10, 2026, he exercised stock options to acquire 3,955 shares of common stock at an exercise price of $8.33 per share. The same day, he sold 4,355 common shares at a weighted average price of $40.0033 per share in open-market transactions under a Rule 10b5-1 trading plan adopted on August 15, 2025. Following these transactions, he directly holds 31,339 common shares and retains 118,696 stock options that are fully vested and exercisable and expire on March 19, 2034.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider TZIANABOS ARTHUR

Role Interim Executive Chair

Sold 4,355 shs ($174K)

Approx. gross sale proceeds $174K

Approx. exercise cost $33K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	3,955	$0.00	$0.00
Exercise	Common Stock	3,955	$8.33	$33K
Sale	Common Stock	4,355	$40.0033	$174K

Holdings After Transaction: Stock Option (Right to Buy) — 118,696 contracts (Direct); Common Stock — 31,339 shares (Direct)

Footnotes (3)

1. F1. The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2025.
2. F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.095 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. Effective October 6, 2025, this option became fully vested and exercisable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Stoke Therapeutics (STOK) Interim Executive Chair Arthur Tzianabos report in this Form 4?

Arthur Tzianabos reported an option exercise and related stock sale. He exercised options for 3,955 shares at $8.33, then sold 4,355 common shares at a weighted average price of $40.0033 per share on March 10, 2026 under a Rule 10b5-1 plan.

How many Stoke Therapeutics (STOK) shares did Arthur Tzianabos sell, and at what price?

He sold 4,355 shares of Stoke Therapeutics common stock. These were open-market transactions at a weighted average price of $40.0033 per share, with individual trades executed between $40.00 and $40.095 per share, according to the Form 4 footnote disclosure.

Were Arthur Tzianabos’ Stoke Therapeutics (STOK) stock sales pre-planned?

Yes. The Form 4 states the reported transaction was executed under a Rule 10b5-1 trading plan adopted on August 15, 2025. Such plans allow insiders to pre-schedule trades, reducing the significance of trade timing as a signal of their current views.

How many Stoke Therapeutics (STOK) shares and options does Arthur Tzianabos hold after these transactions?

After the transactions, he directly holds 31,339 shares of Stoke Therapeutics common stock. He also holds 118,696 stock options that are fully vested, exercisable, and scheduled to expire on March 19, 2034, based on the Form 4 data and footnotes.

What were the terms of the Stoke Therapeutics (STOK) options exercised by Arthur Tzianabos?

He exercised stock options covering 3,955 underlying shares of common stock. These options had an exercise price of $8.33 per share, became fully vested and exercisable effective October 6, 2025, and are scheduled to expire on March 19, 2034, according to the filing.

Does this Stoke Therapeutics (STOK) Form 4 show any remaining unexercised options for Arthur Tzianabos?

Yes. The Form 4 indicates that after exercising 3,955 options, Tzianabos continues to hold 118,696 stock options. These options are fully vested and exercisable and carry an expiration date of March 19, 2034, as described in the transaction details and related footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/12/2026 - 04:57 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TZIANABOS ARTHUR

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim Executive Chair

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/10/2026		M		3,955	A	$8.33	35,694	D
Common Stock	03/10/2026		S(1)		4,355	D	$40.0033(2)	31,339	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.33	03/10/2026		M			3,955	(3)	03/19/2034	Common Stock	3,955	$0	118,696	D

Explanation of Responses:

1. The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.095 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. Effective October 6, 2025, this option became fully vested and exercisable.

	/s/ Jonathan Allan, Attorney-in-Fact	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.